See more : Albert David Limited (ALBERTDA.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Vertex Pharmaceuticals Incorporated (VRTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vertex Pharmaceuticals Incorporated, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- E-Starco. Co. Ltd (015020.KS) Income Statement Analysis – Financial Results
- Feytech Holdings Berhad (5322.KL) Income Statement Analysis – Financial Results
- China Everbright Environment Group Limited (CHFFF) Income Statement Analysis – Financial Results
- Soda Nikka Co., Ltd. (8158.T) Income Statement Analysis – Financial Results
- Atico Mining Corporation (ATY.V) Income Statement Analysis – Financial Results
Vertex Pharmaceuticals Incorporated (VRTX)
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.87B | 8.93B | 7.57B | 6.21B | 4.16B | 3.05B | 2.49B | 1.70B | 1.03B | 580.42M | 1.21B | 1.53B | 1.41B | 143.37M | 102.05M | 175.50M | 199.01M | 216.36M | 160.89M | 102.72M | 69.14M | 161.09M | 167.49M | 78.13M | 61.60M | 44.40M | 43.80M | 13.30M | 22.10M | 19.60M | 27.90M | 3.80M | 3.20M | 2.30M |
| Cost of Revenue | 1.26B | 1.08B | 904.20M | 736.30M | 547.76M | 409.54M | 275.12M | 210.46M | 125.54M | 60.99M | 130.28M | 279.89M | 80.51M | 12.73M | 14.20M | 15.69M | 13.90M | 12.17M | 10.10M | 5.65M | 3.13M | 28.28M | 39.63M | 4.08M | -3.40M | -4.50M | -3.60M | -3.20M | -3.70M | -3.50M | -3.90M | -2.80M | -1.80M | 0.00 |
| Gross Profit | 8.61B | 7.85B | 6.67B | 5.47B | 3.62B | 2.64B | 2.21B | 1.49B | 906.79M | 519.43M | 1.08B | 1.25B | 1.33B | 130.64M | 87.85M | 159.82M | 185.11M | 204.19M | 150.79M | 97.07M | 66.02M | 132.80M | 127.86M | 74.05M | 65.00M | 48.90M | 47.40M | 16.50M | 25.80M | 23.10M | 31.80M | 6.60M | 5.00M | 2.30M |
| Gross Profit Ratio | 87.21% | 87.90% | 88.06% | 88.14% | 86.84% | 86.56% | 88.95% | 87.64% | 87.84% | 89.49% | 89.25% | 81.67% | 94.29% | 91.12% | 86.08% | 91.06% | 93.01% | 94.38% | 93.72% | 94.50% | 95.48% | 82.44% | 76.34% | 94.78% | 105.52% | 110.14% | 108.22% | 124.06% | 116.74% | 117.86% | 113.98% | 173.68% | 156.25% | 100.00% |
| Research & Development | 3.16B | 2.54B | 3.05B | 1.83B | 1.75B | 1.42B | 1.32B | 1.05B | 996.17M | 855.51M | 918.78M | 806.19M | 707.71M | 637.42M | 550.69M | 516.29M | 513.05M | 371.71M | 248.54M | 192.16M | 199.64M | 203.02M | 148.67M | 84.92M | 72.20M | 58.70M | 51.60M | 35.20M | 41.50M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 401.43M | 352.58M | 289.21M | 342.74M | 378.20M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 31.40M | 24.50M | 16.20M | 19.60M | 58.60M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.14B | 944.70M | 840.10M | 770.46M | 658.50M | 557.62M | 496.08M | 432.83M | 377.08M | 305.41M | 362.34M | 436.80M | 400.72M | 187.80M | 129.30M | 101.91M | 84.73M | 57.86M | 43.99M | 42.14M | 39.08M | 49.39M | 47.34M | 27.81M | 26.10M | 18.10M | 11.40M | 7.90M | 7.10M | 40.30M | 26.70M | 13.80M | 8.80M | 6.40M |
| Other Expenses | 475.50M | -164.80M | 4.90M | 296.42M | 192.18M | -790.00K | -81.38M | 4.13M | -6.71M | 30.40M | -72.67M | 44.99M | 124.75M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.30M | 4.50M | 3.60M | 3.20M | 3.70M | 3.50M | 3.90M | 2.80M | 1.80M | 0.00 |
| Operating Expenses | 4.78B | 3.49B | 3.89B | 2.60B | 2.41B | 1.97B | 1.82B | 1.48B | 1.37B | 1.16B | 1.28B | 1.24B | 1.11B | 825.22M | 679.98M | 618.20M | 597.78M | 429.57M | 292.53M | 234.30M | 238.72M | 252.41M | 196.01M | 112.73M | 104.60M | 81.30M | 66.60M | 46.30M | 52.30M | 43.80M | 30.60M | 16.60M | 10.60M | 6.40M |
| Cost & Expenses | 6.04B | 4.57B | 4.80B | 3.34B | 2.96B | 2.38B | 2.10B | 1.69B | 1.50B | 1.22B | 1.41B | 1.52B | 1.19B | 837.95M | 694.18M | 633.89M | 611.69M | 441.74M | 302.63M | 239.95M | 241.84M | 280.69M | 235.64M | 116.81M | 101.20M | 76.80M | 63.00M | 43.10M | 48.60M | 40.30M | 26.70M | 13.80M | 8.80M | 6.40M |
| Interest Income | 614.70M | 144.60M | 4.90M | 22.24M | 63.68M | 0.00 | 11.75M | 0.00 | 0.00 | 0.00 | 0.00 | 1.94M | 1.88M | 1.96M | 5.01M | 16.33M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 44.10M | 54.80M | 61.50M | 58.15M | 58.50M | 34.12M | 57.55M | 81.43M | 84.21M | 72.86M | 22.73M | 14.71M | 36.57M | 19.28M | 13.19M | 13.47M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 181.30M | 148.30M | 125.60M | 109.52M | 106.94M | 72.42M | 61.40M | 61.40M | 62.34M | 63.26M | 48.37M | 38.19M | 35.04M | 30.46M | 30.11M | 32.20M | 27.46M | 25.87M | 27.29M | 29.64M | 23.44M | 25.43M | 17.96M | 9.10M | 6.30M | 4.50M | 3.60M | 3.20M | 3.70M | 3.50M | 3.90M | 2.80M | 1.80M | 0.00 |
| EBITDA | 4.61B | 4.44B | 2.92B | 3.28B | 1.56B | 706.78M | 103.26M | 75.46M | -411.25M | -598.76M | -554.75M | 42.46M | 133.94M | -704.89M | -598.88M | -426.19M | -385.21M | -199.52M | -114.45M | -107.59M | -264.53M | -123.05M | -97.14M | -24.65M | -44.30M | -43.20M | -15.60M | -36.30M | -22.80M | -17.20M | 5.10M | -7.20M | -3.80M | -4.10M |
| EBITDA Ratio | 46.66% | 48.65% | 36.82% | 51.37% | 35.02% | 21.76% | 12.51% | 0.90% | -45.83% | -105.28% | 41.63% | 0.27% | 15.72% | -461.86% | -531.80% | -260.35% | -189.99% | -93.32% | -56.52% | -101.15% | -96.10% | -58.43% | -14.39% | -18.77% | -52.92% | -62.84% | -35.62% | -127.07% | -128.05% | -106.12% | 13.26% | -242.11% | -143.75% | -178.26% |
| Operating Income | 4.31B | 4.31B | 2.78B | 2.86B | 1.20B | 635.15M | 123.24M | 9.94M | -468.66M | -692.41M | -903.45M | 2.33M | 113.82M | -696.08M | -613.41M | -462.71M | -419.79M | -229.04M | -149.87M | -154.81M | -264.53M | -119.60M | -91.80M | -38.68M | -39.60M | -32.40M | -19.20M | -29.80M | -26.50M | -20.70M | 1.20M | -10.00M | -5.60M | -4.10M |
| Operating Income Ratio | 43.65% | 48.23% | 36.73% | 46.03% | 28.77% | 20.84% | 4.95% | 0.58% | -45.40% | -119.30% | -74.54% | 0.15% | 8.07% | -485.51% | -601.10% | -263.65% | -210.94% | -105.86% | -93.15% | -150.71% | -382.59% | -74.25% | -54.81% | -49.51% | -64.29% | -72.97% | -43.84% | -224.06% | -119.91% | -105.61% | 4.30% | -263.16% | -175.00% | -178.26% |
| Total Other Income/Expenses | 72.30M | -75.00M | -51.70M | 62.80M | 197.42M | -34.91M | -138.93M | -77.30M | -90.92M | -42.46M | -366.11M | -59.11M | -53.38M | -58.55M | -28.17M | 2.86M | 28.51M | 21.10M | -53.55M | -11.44M | 67.76M | 28.30M | -2.79M | -16.16M | 10.30M | 0.00 | 0.00 | 0.00 | 5.50M | 3.60M | 900.00K | 2.00M | 800.00K | 4.10M |
| Income Before Tax | 4.38B | 4.23B | 2.73B | 3.12B | 1.39B | 600.24M | -15.69M | -67.37M | -559.58M | -734.88M | -976.12M | -12.38M | 60.45M | -754.63M | -642.18M | -464.18M | -426.91M | -206.89M | -173.39M | -158.51M | -347.35M | -119.66M | -117.89M | -53.61M | -40.30M | 0.00 | 0.00 | -39.50M | -21.00M | -17.10M | 2.10M | -8.00M | -4.80M | 0.00 |
| Income Before Tax Ratio | 44.38% | 47.39% | 36.05% | 50.22% | 33.51% | 19.70% | -0.63% | -3.96% | -54.21% | -126.61% | -80.54% | -0.81% | 4.28% | -526.35% | -629.28% | -264.48% | -214.52% | -95.63% | -107.77% | -154.31% | -502.38% | -74.28% | -70.39% | -68.62% | -65.42% | 0.00% | 0.00% | -296.99% | -95.02% | -87.24% | 7.53% | -210.53% | -150.00% | 0.00% |
| Income Tax Expense | 760.20M | 910.40M | 388.30M | 405.15M | 218.11M | -1.49B | -107.32M | 16.67M | 30.38M | 6.96M | -288.57M | 38.75M | 19.27M | 19.28M | 19.34M | -30.73M | -21.39M | -18.50M | 61.68M | 29.01M | 24.06M | -10.98M | -1.92M | 976.00K | 1.40M | 700.00K | 600.00K | 10.20M | -5.00M | -3.10M | 100.00K | -1.50M | -500.00K | 4.30M |
| Net Income | 3.62B | 3.32B | 2.34B | 2.71B | 1.18B | 2.10B | 263.48M | -112.05M | -558.12M | -738.56M | -445.03M | -107.03M | 29.57M | -754.63M | -641.58M | -459.85M | -391.28M | -206.89M | -203.42M | -166.25M | -196.77M | -108.62M | -66.23M | -39.66M | -41.00M | -33.10M | -19.80M | -40.00M | -21.50M | -17.60M | 2.00M | -8.50M | -5.10M | -4.30M |
| Net Income Ratio | 36.68% | 37.20% | 30.92% | 43.70% | 28.27% | 68.80% | 10.59% | -6.58% | -54.06% | -127.25% | -36.72% | -7.01% | 2.10% | -526.35% | -628.70% | -262.02% | -196.61% | -95.63% | -126.43% | -161.85% | -284.59% | -67.43% | -39.54% | -50.76% | -66.56% | -74.55% | -45.21% | -300.75% | -97.29% | -89.80% | 7.17% | -223.68% | -159.38% | -186.96% |
| EPS | 14.05 | 12.97 | 9.09 | 10.44 | 4.58 | 8.25 | 1.06 | -0.46 | -2.32 | -3.14 | -1.98 | -0.50 | 0.14 | -3.77 | -3.70 | -3.27 | -3.03 | -1.83 | -2.28 | -2.12 | -2.56 | -1.43 | -0.89 | -0.59 | -0.80 | -0.65 | -0.41 | -1.07 | -0.63 | -0.56 | 0.08 | -0.35 | -0.35 | -0.33 |
| EPS Diluted | 13.89 | 12.82 | 9.01 | 10.29 | 4.51 | 8.09 | 1.04 | -0.46 | -2.31 | -3.14 | -1.98 | -0.50 | 0.14 | -3.77 | -3.70 | -3.27 | -3.03 | -1.83 | -2.28 | -2.12 | -2.56 | -1.43 | -0.89 | -0.59 | -0.80 | -0.65 | -0.41 | -1.07 | -0.63 | -0.56 | 0.08 | -0.35 | -0.35 | -0.33 |
| Weighted Avg Shares Out | 257.70M | 256.10M | 257.70M | 259.84M | 256.73M | 254.29M | 248.86M | 243.59M | 240.84M | 234.92M | 224.83M | 211.95M | 204.89M | 200.40M | 173.26M | 140.56M | 128.99M | 113.22M | 89.24M | 78.57M | 77.00M | 75.75M | 74.46M | 67.68M | 51.04M | 50.60M | 48.53M | 37.38M | 34.13M | 31.43M | 25.00M | 24.29M | 14.62M | 13.03M |
| Weighted Avg Shares Out (Dil) | 260.50M | 259.10M | 259.90M | 263.40M | 260.67M | 259.19M | 253.23M | 244.69M | 241.31M | 235.31M | 224.91M | 211.95M | 208.81M | 200.40M | 173.26M | 140.56M | 128.99M | 113.22M | 89.24M | 78.57M | 77.00M | 75.75M | 74.46M | 67.68M | 51.04M | 50.60M | 48.53M | 37.38M | 34.13M | 31.43M | 25.00M | 24.29M | 14.62M | 13.03M |
Vertex Pharmaceuticals: Strong Execution Continued In Q3 But The Valuation Reflects It
Vertex reported strong Q3 results driven by the growth of the cystic fibrosis franchise and raised the full-year revenue guidance range by $100 million at the mid-point. Casgevy finally generated commercial revenue in Q3 and Vertex continues to work in...
Hunting For Magnificent Growth Next Year? Check Out These 7 Stocks.
None of our picks is Nvidia or Amazon or Tesla. Investors may wish to widen the aperture to find the best stocks for outsize earnings growth.
VRTX Q3 Earnings & Sales Trump Estimates, '24 Sales View Raised
Vertex's third-quarter 2024 earnings and revenues beat estimates. The company raises its full-year product revenue guidance.
5 Top Stocks to Buy in November
From blue chip dividend stocks to industry-leading growth stocks, there are plenty of bargains in today's market if you know where to look.
My 2 Favorite Growth Stocks to Buy Hand Over Fist in November
The sky's the limit for these stocks.
Vertex Pharmaceuticals Incorporated (VRTX) Q3 2024 Earnings Call Transcript
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) Q3 2024 Earnings Conference Call November 4, 2024 4:30 PM ET Company Participants Susie Lisa - Senior Vice President, Investor Relations Dr. Reshma Kewalramani - President and CEO Stuart Arbuckle - Chief Operating Officer Charlie...
Vertex Pharmaceuticals (VRTX) Q3 Earnings and Revenues Top Estimates
Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $4.38 per share, beating the Zacks Consensus Estimate of $4.13 per share. This compares to earnings of $4.08 per share a year ago.
Vertex Pharmaceuticals Beats Third-Quarter Estimates As Pain Treatment Looms
Vertex Pharmaceuticals beat third-quarter expectations on Monday. Though the company raised its sales outlook, Vertex stock was muted.
Vertex Pharma lifts annual revenue forecast on cystic fibrosis treatments strength
Vertex Pharmaceuticals raised its annual revenue forecast on Monday after it beat third-quarter estimates on demand for its cystic fibrosis (CF) treatments.
Vertex Reports Third Quarter 2024 Financial Results
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2024, and raised its full-year product revenue guidance to $10.8 billion to $10.9 billion. “The third quarter marked another period of strong...
Source: https://incomestatements.info
Category: Stock Reports